xmab412 monoclonal bispecific antibody
xmab412 monoclonal bispecific antibody: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Lead developer: Xencor Inc (XNCR)
Development Pipeline (1)
| Company | Phase |
|---|---|
| Xencor Inc (XNCR) | Phase 1 |
Clinical Trials (1)
A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple-dose Escalation Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of XmAb412 in Healthy Adult Participants
Frequently asked questions
Who is developing xmab412 monoclonal bispecific antibody?
xmab412 monoclonal bispecific antibody is being developed by Xencor Inc.
How many clinical trials involve xmab412 monoclonal bispecific antibody?
BioSniper tracks 1 clinical trial involving xmab412 monoclonal bispecific antibody.
Analyze Xencor Inc & xmab412 monoclonal bispecific antibody with AI
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
- 200 free AI credits / month to run live multi-agent analysis
- Watchlist, catalyst alerts & the biotech event calendar
- Full pipeline, financials & FDA data on every company